Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ARX788 in HER2-positive metastatic breast cancer resistant or refractory to prior HER2 therapies
2021-001246-36Phase 2Active
- Sponsor
- Ambrx
- Start
- Dec 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anvatabart opadotin in breast cancer, sponsored by Ambrx. Primary endpoint: Objective response rate by BICR. Started Dec 2021; status: active.
02
Drugs
anvatabart opadotin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2021-001246-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001246-36.